April 13, 2022
Allergan’s BOTOX Cosmetic Celebrates 20th Birthday
Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is celebrating 20th anniversary of FDA’s approval of Botox Cosmetic.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
April 13, 2022
FDA Doesn’t Give Myovant Sciences-Pfizer’s Pain Killer sNDA
Myovant Sciences (NYSE: MYOV) and Pfizer (NYSE: PFE) have announced an update on the Supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) for the management of moderate to severe pain associated with endometriosis.
April 13, 2022
EMA and the EUnetHTA 21 consortium set priorities for their collaboration
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) 21 consortium have published a joint work plan until 2023. The focus of the plan is to prepare, from a methodological and operational perspective, for the coming into application of the Regulation on Health Technology Assessment (EU) 2021/228 in January 2025 after a 3-year implementation period.
April 13, 2022
GSK Buys Sierra Oncology for $1.9bn
GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) have entered into an agreement under which GSK will acquire Sierra Oncology, a California-based, late-stage biopharmaceutical company focused on targeted therapies for the treatment of rare forms of cancer, for $55 per share of common stock in cash representing an approximate total equity value of $1.9 billion (£1.5 billion).
April 13, 2022
Bayer receives approval for precision oncology treatment Vitrakvi in China
The Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Bayer’s larotrectinib, under the brand name Vitrakvi, for the treatment of adult and pediatric patients with advanced solid tumors that harbor a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion. NTRK gene fusions should be identified by a sufficiently validated test.
April 13, 2022
Oxford Biomedica Appoints Namrata P Patel as Non-Executive Director
Oxford Biomedica plc has appointed Ms. Namrata P Patel to the Board as an Independent Non-Executive Director with immediate effect.
April 13, 2022
Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares
Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability…
April 13, 2022
Basilea Reports Preclinical Data on Oncology Drug Candidates BAL0891, Derazantinib and Lisavanbulin at AACR Annual Meeting
Basilea Pharmaceutica Ltd. has reported that promising preclinical data on the anti-cancer activity of its three oncology drug candidates, BAL0891, derazantinib and lisavanbulin, have been presented at the Annual Meeting of the American Association for Cancer Research (AACR) that took place April 8-13, 2022, in New Orleans, USA.
April 13, 2022
Santhera Appoints Shabir Hasham as Chief Medical Officer and Member of the Executive Management Team
Santhera Pharmaceuticals (SIX: SANN) has appointed Shabir Hasham, MD, as Chief Medical Officer (CMO) and a member of Santhera’s Executive Management team, effective May 1, 2022.
April 13, 2022
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Strengthens Board of Directors with Appointment of Highly Accomplished Pharmaceutical and Biotechnology Executive, Laura Hamill
Scilex Holding Company (“Scilex”), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a…